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Abstract Mitochondrial diseases, predominantly mito-
chondrial encephalomyopathy, lactic acidosis, and stroke-
like episodes (MELAS), may occasionally underlie or
coincide with ischemic stroke (IS) in young and middle-
aged individuals. We searched for undiagnosed patients
with MELAS in a target subpopulation of unselected young
IS patients enrolled in the Stroke in Young Fabry Patients
study (sifap1). Among the 3291 IS patients aged
18–55 years recruited to the sifap1 study at 47 centers
across 14 European countries, we identified potential
MELAS patients with the following phenotypic features:
(a) diagnosed cardiomyopathy or (b) presence of two of the
three following findings: migraine, short stature (B165 cm
for males; B155 cm for females), and diabetes. Identified
patients’ blood samples underwent analysis of the common
MELAS mutation, m.3243A[G in the MTTL1 gene of
mitochondrial DNA. Clinical and cerebral MRI features of
the mutation carriers were reviewed. We analyzed blood
samples of 238 patients (177 with cardiomyopathy) leading
to identification of four previously unrecognized MELAS
main mutation carrier-patients. Their clinical and MRI
characteristics were within the expectation for common IS
patients except for severe hearing loss in one patient and
hyperintensity of the pulvinar thalami on T1-weighted MRI
in another one. Genetic testing for the m.3243A[G
MELAS mutation in young patients with IS based on
phenotypes suggestive of mitochondrial disease identifies
previously unrecognized carriers of MELAS main muta-
tion, but does not prove MELAS as the putative cause.
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Introduction
Mitochondrial diseases are a heterogeneous group of disor-
ders caused by the dysfunction of the mitochondrial respi-
ratory chain, the essential common pathway for aerobic ATP
production. Therefore, tissues and organs highly dependent
on oxidative ATP production, such as brain, muscle, and
heart, are preferentially affected. An incidence of approxi-
mately 1–2 cases per 10,000 individuals ranks them amongst
the most common metabolic diseases. They may manifest at
any age, with a wide variability of manifestations [1].
Generally, nuclear DNA abnormalities leading to mito-
chondrial dysfunction manifest in childhood and mitochon-
drial DNA (mtDNA) abnormalities in late childhood and
adulthood. The resulting multisystem disease presents most
commonly with neurological and myopathic features.
Mitochondrial encephalomyelopathy with lactic acidosis and
stroke-like episodes (MELAS) is the most common mtDNA
disease presenting with phenotypic features including short
stature, exercise intolerance, neurosensory hearing loss,
migraine-like headaches, seizures, myopathy, ophthalmo-
plegia, cardiomyopathy, axonal neuropathy, diabetes melli-
tus, pigmentary retinopathy, and renal tubular acidosis [2].
Approximately 80 % of all MELAS patients carry a single
mutation of m.3243A[G in the tRNAleu (UUR) (MTTL1)
within the mtDNA [3].
Mitochondrial diseases are a rare, but well-recognized
cause of ischemic stroke (IS)-like episodes at various ages
[2, 4]. While MELAS is the most common cause, other
mitochondrial diseases such as myoclonic epilepsy with
ragged red fibers (MERRF), Kearns–Sayre syndrome,
Leigh syndrome, mitochondrial recessive ataxia syndrome
(MIRAS), and hyperornithinemia-hyperammonemia-ho-
mocitrullinuria (triple-H syndrome) have also rarely been
reported to be associated with IS-like lesions [4, 5]. The
pathophysiology and course of stroke-like episodes in
patients with mitochondrial diseases are distinct from IS
and are probably underlied by a number of mechanisms—
alone or in combination—discussed in detail elsewhere [4].
We previously reported only two MELAS patients among
1008 young patients with first-ever IS at their age of
15–49 years [6]. Mitochondrial disease was reported in 4
out of 104 Saudi children presenting with stroke [7].
Recently, 6 patients with mitochondrial disease out of 3331
European young first-ever IS patients were reported by us
[8]. However, mitochondrial disease is likely underdiag-
nosed among IS patients and no systematic targeted or
unselected screening approach has been performed.
In the present work, we aimed at detecting undiagnosed
MELAS main mutation (m.3243A[G) carrier-patients in a
large multinational European database of a relatively young
(18–55 years of age at the index IS onset) population of IS
patients recruited to the sifap1 study. We expected undiag-
nosed MELAS patients to be discovered at a relatively low
cost if a phenotype-targeted approach taking into account
‘‘red flags’’ for mitochondrial disease, (e.g., cardiomyopa-
thy, migraine, diabetes, and short stature) would be utilized
for phenotypic prescreening before genetic analyses.
Patients and methods
Patients
The Stroke in Young Fabry Patients (sifap1) is a European
multicenter prospective observational cohort study of white
patients aged 18–55 years who were diagnosed with any
stroke or transient ischemic attack and recruited during
2007–2010 at 47 stroke centers residing in 14 countries.
The study protocol, patient population, and main outcomes
were described in detail elsewhere [9–12]. This study was
approved by the ethics committee at the leading center
(University of Rostock, Rostock, Germany) and in all
participating centers according to their national and insti-
tutional legislation.
Because m.3243A[G is the most frequent mtDNA
mutation, and the most common mitochondrial cause of
stroke-like-episodes disease, we tested patients’ DNAs for
this specific mutation. Among sifap1 patients with IS
(n = 3291), we searched for an enriched patient subpop-
ulation according to the following red flags of the mito-
chondrial diseases associated with m.3243A[G mutation:
(a) diagnosed cardiomyopathy or (b) presence of two of the
following three features: migraine, short stature (B165 cm
for males and B155 cm for females), and diabetes.
Unfortunately, deafness/hearing loss was not recorded in
the database. Blood samples were stored at -80 C and
were available for 238 IS patients who fulfilled the inclu-
sion criteria. Of these, 177 had preexisting cardiomyopathy
and the rest had different combinations of migraine, short
stature, and diabetes mellitus.
Cell materials and DNA-analysis
DNA was extracted by routine methodology from blood
samples. Previous studies have indicated that the amount of
the mutant m.3243A[G mtDNA form decreases by age in
leukocytes [13, 14], and therefore in cases in which a
suspicion for presence of m.3243A[G mutations arose, we
tried to obtain a second sample of urine epithelial cells for
mtDNA analysis, as these cells have shown to represent
well the overall tissue mutant mtDNA load. The presence
of the mutation and quantitation of mtDNA heteroplasmy
was performed by PCR-amplification and solid-phase
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minisequencing methodology, as previously described
[15]. Solid-phase minisequencing method we used is a very
sensitive one, able to detect 1–2 % mutant mtDNA fre-
quencies with high reliability [16].
Magnetic resonance imaging and data collection
In the sifap1 study, all participating sites were free to use
the set of MRI sequences regularly employed at their center
for the imaging of stroke, but the study protocol recom-
mended T2/PD-weighted and/or FLAIR images along with
a diffusion-weighted imaging (DWI) sequence as the
minimum. Imaging data were collected and interpreted
centrally as described elsewhere [9–11]. There was also a
mandatory core data set for the collection of demographic
and clinical patient characteristics as all patients underwent
a detailed evaluation along with all adequate testing. All
data were entered to an electronic database. Patients with
IS (n = 3291) were classified into etiologic subgroups
according to the Trial of Org 10,172 in Acute Ischemic
Stroke Treatment (TOAST) classification. In addition,
clinical and imaging data were reevaluated in detail for
those identified as carriers of the main MELAS mutation.
Results
Four out of the 238 investigated patients, all previously
undiagnosed for MELAS, from four different medical
centers, were found to carry the heteroplasmic m.3243A[G
mtDNA mutation. Detailed patient data are presented in the
Table 1. MELAS mutation load in blood samples was
between 4 (patient 1) and 52 % (patient 2) confirming the
presence of MELAS main mutation in all 4 patients. The
initial TOAST subgroup classification was small-vessel
disease (TOAST 3) in three patients and undetermined
(TOAST 5) in one (patient 3). All patients were imaged
with brain MRI within 2 days of admission. MRI findings
were not specific regarding the infarct pattern or the extent
of concomitant changes in the brain (Table 1; Fig. 1).
Three of four patients demonstrated deep subcortical
infarcts (patients 1–3). No infarct was detected in one
(patient 4). Apart from an ischemic lesion, one patient also
exhibited high signal of the pulvinar thalami bilaterally on
T1-weighted MRI (patient 2).
After mtDNA diagnostics, we were able to reach out to
two patients (patients 2 and 4). One patient (patient 4) had
deafness in addition to already known features and there
were several individuals in the family with short stature
and deafness. The other patient (patient 2) again had suf-
fered several episodes of lactic acidosis and infection after
his stroke and was under investigations for significant
cognitive problems. None of the patients had
ophthalmoplegia, visual disturbances, or seizures. Addi-
tionally, we were able to examine a urine sample from one
patient where the mutation load was 85 %, higher than in
the blood (52 %, patient 2). Unfortunately, the two further
patients could not be reexamined.
Discussion
Testing for the main MELAS mutation in a fairly young
stroke population selected on the basis of specific pheno-
typic features that are suggestive for mitochondrial disease
led to positive findings in four patients (*1.7 %). All these
patients went unrecognized for their MELAS-like pheno-
typic features when they were hospitalized in the acute
phase of their ISs. Thus, our study demonstrates that in a
phenotype-targeted group, a reasonable number of MELAS
mutation carriers can be detected with a rather inexpensive
approach. Using a clinical algorithm similar to ours for
genetic testing for the m.3243A[G MELAS mutation may
well be cost-effective, as the yield for detecting potential
cases of MELAS was rather high with modest costs in this
study. Mitochondrial disease diagnostics are important not
only for the index patient, but also for the family members,
at least in terms of genetic counseling, as several unrec-
ognized additional cases could be found multiplying the
benefits of diagnostic testing in our patients.
Previous studies reported mitochondrial diseases among
consecutive young IS patients to be as low as 2 in 1008 [6]
and 6 among 3331 [8], with higher rates (4 among 104)
among pediatric patients [7]. Underdiagnosis is potentially
possible as all patients in these studies were not system-
atically tested for mitochondrial diseases and no results of
comprehensive testing for mitochondrial diseases in
selected or unselected IS patient series are available.
MELAS diagnostics in the aforementioned studies were
based on clinical suspicion and further genetic counseling,
but no systematic searches were performed. A recent study
demonstrated that less than half (17/41) of MELAS
patients had left ventricular hypertrophy or dysfunction
[17], therefore, our selection criteria and results may well
be underestimating the number of MELAS patients in the
sifap study population. However, since we could not per-
form full-scale mitochondrial disease diagnostic testing in
all our mutation-positive patients, we can only report on
mutation-positive IS patients, whereas aforementioned
young stroke studies confirmed MELAS diagnosis in their
patients with stroke-like episodes [6–8].
MELAS main mutation tested in unselected populations
was found to be 7/2954 among white people in one study
[18] and 4/3168 in neonatal umbilical cord blood samples
from sequential live births in the United Kingdom [19].
Interestingly, all seven individuals in the former study had
J Neurol (2016) 263:257–262 259
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mild to moderate hearing loss [18]. Another recent study
reported that 1/400 were carriers of a MELAS mutation in
the United Kingdom [20]. Of the 129 patients reviewed in
this report, 28 % had clinical features not consistent with
the clinical syndrome and only 9 % of the carriers were
asymptomatic [20]. This further indicates that we could
have missed additional mutation carrying patients using
typical phenotype characteristics to delineate the cohort of
238 patients that was tested. Our mutation carriers are
highly likely to have MELAS rather than being carriers
only: first, they all appeared with ISs; second, they had
major phenotypic features of MELAS; third, we found an
incidence of 1.7 % that is well-above that was found in
general populations (*1 in 1000) [18, 19]; and last, indi-
viduals carrying MELAS mutation are only rarely asymp-
tomatic [20].
Our findings suggest that positive MELAS main muta-
tion is a considerable finding among young to middle-aged
IS patients when they harbor typical phenotypic features
for mitochondrial disease. Furthermore, MELAS may also
be underdiagnosed even at dedicated stroke centers. A
general routine mitochondrial disease genetic search in all
young IS patients may not be warranted given its low cost-
effectiveness, but this has so far not been formally asses-
sed. Considering the experience in general populations
[18–20], the number needed to analyze may be as high as
1000. Probably, it is worth testing for the m.3243A[G
mutation in all young to middle-aged patients with IS-like
episodes harboring the main clinical features of mito-
chondrial disease similar to our algorithm as our approach
delivered a number needed for an analysis of 60. Because
association of other mitochondrial diseases with stroke-like
episodes (e.g., MERRF and MIRAS) are based on indi-
vidual case reports, routine screening for other mitochon-
drial diseases in unselected IS patient populations or even
in young patients is unlikely to be cost-effective. Similar
studies could be completed in distinct ethnic populations as
our findings are only valid for white European-originating
Table 1 Basic characteristics of the 4 ischemic stroke patients diagnosed with MELAS
Patient 1 Patient 2 Patient 3 Patient 4
Age at stroke
onset
46 49 40 46
Gender Male Male Male Female
Family history Unknown Nothing significant Cardiac and renal
disease
Cerebrovascular disease
Symptoms at
admission
Dysarthria, diplopia,
vertigo, hemiparesis
Dysarthria, motor and sensory hemiparesis Diplopia, vertigo Vomiting, ataxia,
vertigo, sensory
symptoms
mtDNA mutation
load (%)
4 52 10 41
Echocardiography Yes Yes Yes Yes
Patent foramen
ovale
No No No No
Thrombolysis No Intravenous thrombolysis No No
Medical history
and risk factors
Migraine, diabetes,
smoking,
cardiomyopathy
Coronary disease, myocardial infarction,
coronary bypass operation, hypertension,
snoring, migraine, diabetes
Cardiomyopathy,
smoking,
snoring
Diabetes, migraine,
hypertension, fatigue
Prior medication Aspirin, statin Clopidogrel, ACE inhibitor, statin None Aspirin, ACE inhibitor,
calcium channel
blocker, diuretic,
statin, insulin
Stature (cm) 181 166 183 155
Weight (kg) 95 63 93 59
Arrival NIHSS
score
9 9 2 3
TOAST
classification
Small-vessel disease Small-vessel disease Undetermined
etiology
Small-vessel disease
MRI findings Small acute left medial
thalamic infarct
extending into the
mesencephalon
Acute infarct in the left thalamus extending into
the posterior limb of the internal capsule.
Bilateral T1 signal hyperintensity of pulvinar
thalami
Old infarcts in
left cerebellum
Few punctate white
matter
hyperintensities, no
acute infarct on DWI
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individuals. However, whole mtDNA diagnostic testing is
unlikely to yield additional information as most other
mtDNA abnormalities are not associated with stroke-like
episodes. Whole mtDNA testing is rather costly (*2000€
per sample) and requires substantial expert physician time
to analyze and interpret the findings.
Whether our MELAS main mutation finding was the
cause or a bystander in our patients is not certain, as most
MELAS patients developing stroke-like episodes were
reported to present with multiple cortical infarct-like
changes not confined strictly to arterial territories, a finding
which was not seen in our cohort. Instead, we detected
deep-territory infarcts in two patients, cerebellar infarction
in one patient, and no MRI-visible acute ischemic lesion in
one patient. Unfortunately, we could not reevaluate our
mutation-positive four patients for a definite MELAS
diagnosis. Therefore, a positive MELAS main mutation
finding could only be an incidental finding instead of the
cause, although potentially an under-recognized atypical
pattern of MELAS disease that could easily be overlooked
by physicians is possible. A recent article including 11
patients with MELAS and encephalopathy, but without any
stroke-like episodes reported deep gray matter lesions in
seven of the patients [21]. This supports the view that,
indeed, atypical lesions may not be so rare in the absence
of typical stroke-like episodes. Obviously, we cannot
conclude MELAS as the putative cause in these patients.
Initially, three out of four patients were classified as having
small-vessel disease and one as having stroke of undeter-
mined etiology according to the TOAST classification by
the treating physicians. Thus, mitochondrial disease was
not considered in any patient. Notably, despite preexisting
cardiomyopathy in two patients, in neither patient was
cardiogenic embolism considered a cause of IS.
Strengths of our study are the large source patient
population and the well-documented phenotypic charac-
teristics. One of the main limitations, in turn, is the fact that
we did not test mitochondrial disease in all study partici-
pants and reserved testing to those with phenotypic features
for mitochondrial diseases. Therefore, we are not certain
whether routine screening of young IS patients for MELAS
disease would have yielded additional patients. Moreover,
we tested only for the m.3243A[G mutation, which covers
approximately 80 % of all MELAS patients [3]. Therefore,
our results may still be an underestimation. Furthermore,
we could not reach out to two of the four MELAS muta-
tion-positive patients for further scrutiny of family history.
Our patient population is also limited to white European
patients, which diminishes the generalizability of our
findings to other populations.
In conclusion, mtDNA testing for MELAS in a rela-
tively young IS patient population with phenotypic tar-
geting may disclose a considerable number of previously
unrecognized MELAS main mutation carrying patients at a
reasonable cost. However, it remains uncertain whether
mitochondrial disease was the cause of ISs in our 4 patients
and to what extent our approach underestimates the overall
frequency of MELAS mutations in such populations.
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Fig. 1 Magnetic resonance images depicted from all four patients.
White arrows indicate infarcts. a Patient 1 with left acute medial
thalamic infarct extending into mesencephalon (DWI), b patient 2
with acute infarct in the left thalamus extending into the posterior
limb of the internal capsule (FLAIR), c patient 3 demonstrating old
infarcts in left cerebellum (T2), and d patient 4 showing few punctate
white matter hyperintensities, but no acute infarction on MRI
(FLAIR)
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